AXGN
Axogen·NASDAQ
--
--(--)
--
--(--)
AXGN fundamentals
Axogen (AXGN) released its earnings on Feb 24, 2026: revenue was 59.90M (YoY +21.25%), beat estimates; EPS was 0.07 (YoY 0.00%), missed estimates.
Revenue / YoY
59.90M
+21.25%
EPS / YoY
0.07
0.00%
Report date
Feb 24, 2026
AXGN Earnings Call Summary for Q4,2025
- Revenue Growth: 2025 revenue up 20.2% to $225.2M, EBITDA +41% to $27.9M.
- FDA Breakthrough: Avance becomes first FDA-approved nerve repair biologic with 12-year exclusivity.
- 2026 Guidance: ≥18% revenue growth ($265.7M+), 74-76% gross margin, free cash flow positive.
- Market Expansion: 130 extremities reps by end-2026, 30 breast reps, 100+ prostate procedures in 2025.
- Margin Dynamics: 2026 gross margin pressure from biologic transition, 2027+ improvement via scale.
EPS
Actual | -0.19 | -0.15 | 0.04 | -0.08 | -0.08 | -0.09 | -0.09 | -0.08 | -0.2 | -0.06 | -0.01 | -0.03 | -0.1 | -0.03 | 0.01 | -0.06 | -0.06 | 0.05 | 0.07 | 0.07 | -0.02 | 0.12 | 0.12 | 0.07 | ||||||||||
Forecast | -0.1533 | -0.3383 | -0.142 | -0.1147 | -0.1686 | -0.1308 | -0.1267 | -0.1315 | -0.1513 | -0.1543 | -0.126 | -0.1132 | -0.142 | -0.1212 | -0.064 | -0.0715 | -0.068 | -0.064 | 0.006 | 0.0356 | 0.0146 | 0.0636 | 0.0722 | 0.09 | ||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -23.94% | +55.66% | +128.17% | +30.25% | +52.55% | +31.19% | +28.97% | +39.16% | -32.19% | +61.11% | +92.06% | +73.50% | +29.58% | +75.25% | +115.63% | +16.08% | +11.76% | +178.13% | +1066.67% | +96.63% | -236.99% | +88.68% | +66.20% | -22.22% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.26M | 22.12M | 33.43M | 32.49M | 31.04M | 33.58M | 31.20M | 31.54M | 31.01M | 34.50M | 36.96M | 36.20M | 36.66M | 38.16M | 41.27M | 42.90M | 41.38M | 47.91M | 48.64M | 49.41M | 48.56M | 56.66M | 60.08M | 59.90M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 26.21M | 16.46M | 27.37M | 30.27M | 27.87M | 32.18M | 33.67M | 31.79M | 30.33M | 33.82M | 36.20M | 36.20M | 35.37M | 39.08M | 40.45M | 41.25M | 41.96M | 43.37M | 47.07M | 48.57M | 48.30M | 52.66M | 56.94M | 59.17M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7.42% | +34.35% | +22.11% | +7.36% | +11.35% | +4.35% | -7.33% | -0.80% | +2.22% | +2.01% | +2.09% | -0.01% | +3.67% | -2.37% | +2.03% | +4.00% | -1.38% | +10.48% | +3.35% | +1.72% | +0.53% | +7.60% | +5.51% | +1.23% |
Earnings Call
You can ask Aime
What were the key takeaways from Axogen’s earnings call?What is Axogen's latest dividend and current dividend yield?What factors drove the changes in Axogen's revenue and profit?Did Axogen beat or miss consensus estimates last quarter?What is Axogen's gross profit margin?What does Axogen do and what are its main business segments?What is the market's earnings forecast for Axogen next quarter?What were the key takeaways from Axogen's earnings call?
